Skip to content

Healthcare and Pharmaceuticals

Total current expenditure on health as a share of gross domestic product (GDP) in Slovenia is 8,3 % (3,813 billion EUR). Most of the health care funds are used for services of curative care in hospitals (41,3%) and ambulatory care (22,9%), for medical goods (21,6%), and for long-term care (9.1%). It is expected that healthcare spending will increase as the population rapidly ages, and will offer commercial opportunities for pharmaceutical and other healthcare companies, in conjunction with a high standard healthcare and increased demand for treatment.

Slovenia has a small domestic production of healthcare equipment and healthcare devices. Instruments and equipment are mainly imported. The Covid-19 crisis has shown the need for upgrading the aging technology and equipment in the healthcare system. Strong investments in healthcare and elderly care system are necessary, therefore the government is committed towards reforms, healthcare infrastructure construction and modernisation over the coming years. From the NextGenerationEU recovery fund Slovenia is expected to allocate around 300 million EUR to improve the healthcare system and long-term care until 2026. Most of the money for this fund will be used for digitalisation of healthcare and telemedicine, for investments in capacity needed for effective treatment and monitoring of contagious diseases and related epidemic control measures (140 million EUR), for nursing homes with equipment and for ensuring a safe living environment for people who depend on the help of others (99 million EUR).

Current per capita pharmaceutical expenditure in Slovenia is about 400 EUR. There is a considerable generic manufacturing capacity in Slovenia through local and other multinational drug companies with production facilities in the country. The local pharmaceutical producers have focus on generic drugs and more than 95% of pharmaceutical products are exported. On the other hand, the demand for biological and targeted prescription drugs for treatment of cancer, cardiovascular diseases, and other biological medications is increasing and accordingly the market offers good opportunities for producers of innovative drugs.

Local and other multinational drug companies have strong R&D departments and are working closely with the scientific institutes and universities. These institutions play a major role in the creation of small innovative companies and create opportunities also for foreign investments. Some of the leading global pharmaceutical and biotech companies established development centres in Slovenia for development of advanced technologies or invested in start-ups.

CONTACT

Royal Danish Embassy 
Trg N. Š. Zrinskog 10
HR-10000 Zagreb
Croatia

Tel. +385 1 4924 530
Fax +385 1 4924 554

E-mail zagamb@um.dk

 

The Trade Council - Croatia/Slovenia/Albania/Kosovo

Zarko Masanovic
Head of Trade Department
Mob. +385 91 49 24 550
Tel. +385 1 4924 550
E-mail zarmas@um.dk

 

Christian Maric 

Political/Economic & Commercial Assistant

Mob. +385 1 492 4545

Tel. +385 91 492 4540

E-mail chrmai@um.dk    

 

Albania & Kosovo

Almira Pajenga
Partner
Tel. + 355 69 202 97 32 (Albania)
Tel. + 377 44 58 13 85 (Kosovo)
E-mail alma@urbandanish.solutions

Email Albania albania@urbandanish.solutions

Email Kosovo kosovo@urbandanish.solutions

 

Regional Coordinator

Anette Snedgaard Galskjøt
Regional Coordinator

Tel. +90 212 359 19 03

Mobile +90 53 489 322 29
E-mail anegal@um.dk